HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

N Brünner Selected Research

Tissue Inhibitor of Metalloproteinases

1/2009Changes in plasma TIMP-1 levels after resection for primary colorectal cancer.
1/2008Identifying sources and estimating glandular output of salivary TIMP-1.
4/2007Investigation of tissue inhibitor of metalloproteinases 1 in plasma from colorectal cancer patients and blood donors by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.
1/2006Levels of tissue inhibitor of metalloproteinases 1 in plasma and urine from patients with bladder cancer.
5/2005Quantification of tissue inhibitor of metalloproteinases 2 in plasma from healthy donors and cancer patients.
1/2004Association between preoperative plasma levels of tissue inhibitor of metalloproteinases 1 and rectal cancer patient survival. a validation study.
11/2000High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


N Brünner Research Topics

Disease

30Neoplasms (Cancer)
09/2014 - 02/2000
16Breast Neoplasms (Breast Cancer)
09/2007 - 02/2000
15Colorectal Neoplasms (Colorectal Cancer)
02/2011 - 02/2000
5Neoplasm Metastasis (Metastasis)
06/2005 - 01/2001
4Rectal Neoplasms (Rectal Cancer)
01/2007 - 03/2001
3Carcinoma (Carcinomatosis)
09/2014 - 04/2000
2Colonic Neoplasms (Colon Cancer)
09/2007 - 03/2006
1Cardiovascular Diseases (Cardiovascular Disease)
01/2008
1Fibrosarcoma
10/2006
1Wounds and Injuries (Trauma)
03/2006
1Adenoma (Adenomas)
01/2006
1Urinary Bladder Neoplasms (Bladder Cancer)
01/2006
1Adenocarcinoma
01/2006
1Infections
01/2006
1Cystitis
01/2006
1Breast Diseases (Breast Disease)
07/2005
1Inflammation (Inflammations)
08/2004
1Osteolysis
01/2004
1Psoriasis (Pustulosis Palmaris et Plantaris)
11/2002
1Endometrial Neoplasms (Endometrial Cancer)
12/2001
1Uterine Diseases (Endometrial Disease)
09/2001
1Uterine Cervical Neoplasms (Cancer of the Cervix)
09/2001
1Crohn Disease (Crohn's Disease)
03/2001
1Necrosis
03/2001
1Tetanus
03/2001

Drug/Important Bio-Agent (IBA)

13Tissue Inhibitor of Metalloproteinase-1IBA
02/2011 - 11/2000
9Plasminogen Activator Inhibitor 1IBA
07/2005 - 02/2000
8Plasminogen Activators (Plasminogen Activator)IBA
07/2005 - 09/2000
8Urokinase-Type Plasminogen Activator (Urokinase)FDA Link
05/2003 - 02/2000
7Tissue Inhibitor of MetalloproteinasesIBA
01/2009 - 11/2000
6Urokinase Plasminogen Activator ReceptorsIBA
04/2005 - 02/2000
5Messenger RNA (mRNA)IBA
09/2014 - 08/2001
5Proteins (Proteins, Gene)FDA Link
01/2007 - 08/2001
5Plasminogen InactivatorsIBA
12/2001 - 09/2000
4Biomarkers (Surrogate Marker)IBA
01/2008 - 03/2002
3Tissue ExtractsIBA
01/2007 - 12/2000
3AntigensIBA
07/2005 - 02/2000
3beta-Galactosidase (Lactaid)IBA
01/2004 - 05/2000
3Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
11/2002 - 11/2000
3EnzymesIBA
12/2001 - 05/2000
3PlasminogenIBA
03/2001 - 02/2000
2Progesterone Receptors (Progesterone Receptor)IBA
09/2014 - 04/2001
2Plasminogen Activator Inhibitor 2IBA
07/2005 - 02/2000
2Protease Inhibitors (Protease Inhibitor)IBA
06/2005 - 02/2000
2Edetic Acid (EDTA)FDA Link
05/2005 - 11/2000
2Citric Acid (Citrate)FDA LinkGeneric
05/2005 - 09/2001
2Immunoglobulin G (IgG)IBA
11/2003 - 04/2000
2TamoxifenFDA LinkGeneric
11/2003 - 08/2001
2Monoclonal AntibodiesIBA
11/2003 - 04/2000
2Peptide Hydrolases (Proteases)FDA Link
08/2001 - 03/2001
2Cystatin CIBA
05/2001 - 02/2000
2C-Reactive ProteinIBA
03/2001 - 09/2000
1Protein Isoforms (Isoforms)IBA
09/2014
1SYBR Green IIBA
09/2014
1RNA IsoformsIBA
09/2014
1Formaldehyde (Formol)FDA Link
09/2014
1ParaffinIBA
09/2014
1Carcinoembryonic AntigenIBA
02/2011
1XELOXIBA
02/2011
1Capecitabine (Xeloda)FDA Link
02/2011
1Oxaliplatin (Eloxatin)FDA LinkGeneric
02/2011
1Tissue Inhibitor of Metalloproteinase-2IBA
05/2005
1Cysteine Proteases (Cysteine Protease)IBA
10/2004
1Cathepsin HIBA
10/2004
1Glycoproteins (Glycoprotein)IBA
08/2004
1Ibandronic Acid (Boniva)FDA Link
01/2004
1Diphosphonates (Bisphosphonates)IBA
01/2004
1Estrogen Receptor Modulators (Antiestrogen)IBA
09/2003
1Aromatase (CYP19)IBA
09/2003
1Estrogen Receptor betaIBA
09/2003
1Estrogen Receptor alphaIBA
09/2003
1Detergents (Detergent)IBA
05/2003
1Pharmaceutical PreparationsIBA
03/2002
1Keratins (Keratin)IBA
01/2002
1ImmunosorbentsIBA
12/2001
1Estrogens (Estrogen)FDA Link
08/2001
1Matrix Metalloproteinases (MMPs)IBA
08/2001
1Matrix Metalloproteinase InhibitorsIBA
08/2001
1batimastat (BB 94)IBA
08/2001
1Metalloproteases (Metalloproteinases)IBA
08/2001
1Extracellular Matrix ProteinsIBA
07/2001
1FibrinolysinFDA Link
07/2001
1Cathepsin BIBA
05/2001
1Estrogen ReceptorsIBA
04/2001
1Histamine (Histamine Dihydrochloride)FDA Link
03/2001
1Peroxidase (Myeloperoxidase)IBA
03/2001
1Phenobarbital (Luminal)FDA Link
03/2001
1Tetanus Toxoid (Vaccine, Tetanus)FDA Link
03/2001
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
03/2001
1VaccinesIBA
03/2001
1Interleukin-6 (Interleukin 6)IBA
03/2001
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
03/2001
1Angiogenesis Inducing Agents (Angiogenesis Factor)IBA
11/2000
1Biological ProductsIBA
11/2000
1Doxorubicin (Adriamycin)FDA LinkGeneric
05/2000

Therapy/Procedure

6Therapeutics
06/2005 - 02/2000
1Combination Drug Therapy (Combination Chemotherapy)
02/2011
1Lasers (Laser)
04/2007
1Drug Therapy (Chemotherapy)
10/2006
1Blood Transfusion (Blood Transfusions)
09/2000